Difference between revisions of "Resource:270a135c-cf51-4a57-81b7-cdd162ea8fdf"
From The Embassy of Good Science
Marc.VanHoof (talk | contribs) |
Marc.VanHoof (talk | contribs) |
||
| Line 2: | Line 2: | ||
|Resource Type=Cases | |Resource Type=Cases | ||
|Title=Fast, cheap, and out of control? Speculations and ethical concerns in the conduct of outsourced clinical trials in India | |Title=Fast, cheap, and out of control? Speculations and ethical concerns in the conduct of outsourced clinical trials in India | ||
| + | |Is About=This article reports the results of a study conducted in Bangalore and Hyderabad between 2007 and 2009, to elicit the perspectives of stakeholders, concerning media representations of their work and the ethical issues that emanate from their engagement in the clinical trials enterprise<ref>https://www.sciencedirect.com/science/article/abs/pii/S0277953613006837</ref>. | ||
| + | |||
| + | |||
| + | This is a factual case. | ||
| + | <references /> | ||
| + | |Important Because=The globalization of biopharmaceutical clinical trials and their offshore outsourcing, from the West to low and middle-income countries, has come under increasing scrutiny from academic scholars, practitioners, regulatory agencies and the media<ref>https://www.sciencedirect.com/science/article/abs/pii/S0277953613006837</ref>. | ||
| + | |||
| + | |||
| + | Journal | ||
| + | <references /> | ||
|Important For=Researchers | |Important For=Researchers | ||
}} | }} | ||
Revision as of 13:35, 18 May 2020
ResourcesCases
Fast, cheap, and out of control? Speculations and ethical concerns in the conduct of outsourced clinical trials in India
What is this about?
This article reports the results of a study conducted in Bangalore and Hyderabad between 2007 and 2009, to elicit the perspectives of stakeholders, concerning media representations of their work and the ethical issues that emanate from their engagement in the clinical trials enterprise[1].
This is a factual case.
Why is this important?
The globalization of biopharmaceutical clinical trials and their offshore outsourcing, from the West to low and middle-income countries, has come under increasing scrutiny from academic scholars, practitioners, regulatory agencies and the media[1].
Journal
